Proteolix proteolix.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Proteolix is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target certain cancers by introducing proteasome inhibition and thereby disrupting protein turnover in cells, particularly cancer cells, which leads to cell death. Proteolix is developing second generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this new target class.

Proteolix is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target certain cancers by introducing proteasome inhibition and thereby disrupting protein turnover in cells, particularly cancer...Show all

Company (Acquired)

Phone: 650-266-2600

Fax:

333 Allerton Avenue

South San Francisco, 94080
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Proteolix $142.3M Oct 12, 2009
See all 18 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Proteolix Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors

Board Members

Competitors

Company Status Description Investors
See all 18 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Substrate for rpn11 enzymatic activity May 30, 2006 Jun 22, 2010 Patent
Compounds for enzyme inhibition Nov 09, 2006 Mar 30, 2010 Patent
Compounds for enzyme inhibition Apr 11, 2007 Feb 17, 2009 Patent